✦ LIBER ✦

187 The role of 3rd therapy in recurrent ovarian carcinoma or primary peritoneal carcinoma

✍ Scribed by A. Sella; D. Schnider; S. Kovel; E. Shapira; R. Halperin; N. Wallach; A. Fishman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of lenalidomide (Rev

✍ Mallory M. Zhang; John K. Chan; Amreen Husain; Hong-Yan Guo; Nelson N.H. Teng 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Phase II evaluation of dasatinib in the

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

Timing of genetic counselling in patient

✍ Novetsky, A.; Smith, K.; Babb, S.; Jeffe, D.; Hagemann, A.; Thaker, P.; Powell, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 69 KB

A phase II study of ramucirumab (IMC-112

✍ Penson, Richard T.; Moore, Kathleen M.; Fleming, Gini F.; Braly, Patricia; Schim 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 637 KB

A phase II study of vorinostat in the tr

✍ Susan C. Modesitt; Michael Sill; James S. Hoffman; David P. Bender 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 251 KB

A phase II evaluation of lapatinib in th

✍ Agustin A. Garcia; Michael W. Sill; Heather A. Lankes; Andrew K. Godwin; Robert 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 220 KB